Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28294649 | 0.81 | NPC1 (0.87) | NPC1DYRK1AMAPTKMT2AMEN1 | |
| SCHEMBL2744059 | 0.81 | NPC1 (0.74) | NPC1DYRK1AMAPTKMT2AMEN1 | |
| SCHEMBL6640492 | 0.81 | CCNT1 (0.58) | DYRK1AKMT2AALDH1A1KDM4ECCNT1 | |
| SCHEMBL15650217 | 0.80 | ADORA2A (0.57) | NPC1DYRK1AKMT2AMEN1AURKA | |
| SCHEMBL16608063 | 0.80 | NPC1 (0.63) | NPC1DYRK1AMAPTKMT2AMEN1 | |
| SCHEMBL2994671 | 0.79 | HSP90AA1 (0.66) | NPC1MAPTKMT2AMEN1AURKA | |
| SCHEMBL3814785 | 0.79 | HDAC1 (0.66) | NPC1MAPTKMT2AMEN1ADORA2A | |
| SCHEMBL21164006 | 0.79 | HSP90AA1 (0.70) | NPC1MAPTKMT2AMEN1AURKA | |
| SCHEMBL210310 | 0.79 | NPC1 (0.61) | NPC1DYRK1AMAPTKMT2AMEN1 | |
| SCHEMBL212750 | 0.79 | NPC1 (0.61) | NPC1DYRK1AMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112010844-B | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-112010844-A | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2020-12-01 | — | — | CN | disclosed |
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2015-09-17 | — | — | US | disclosed |
| US-9056837-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130123269-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8367686-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES INC. | 2010-07-08 | — | — | US | disclosed |
| EP-2166858-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153959-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-0108380-B1 | PYRIDO 2,3-D PYRIDIMIN-5-ONES | STERLING DRUG INC. (US) | 1989-02-22 | — | — | EP | disclosed |
| US-4560753-A | 2-Substituted-pyrido[2,3-d]pyrimidin-5(8H)-ones | STERLING DRUG INC. (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0108380-A2 | Pyrido 2,3-d pyridimin-5-ones | STERLING DRUG INC. (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4432981-A | 2-(Pyridinyl or hydroxyphenyl)-8-substituted pyrido[2,3-d]pyrimidin-5(8H)-ones | STERLING DRUG INC. (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | NPC1 602/4885DYRK1A 2580/4885MAPT 103/4885 |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | NPC1 549/4885DYRK1A 2418/4885MAPT 97/4885 |
| US-20130123269-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | NPC1 602/4885DYRK1A 2580/4885MAPT 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.